Insiders Buy the Holdings of FHLC ETF

The Fidelity MSCI Health Care Index ETF (FHLC) has 12.8% of its weighted underlying holdings showing insider buying activity in the last six months. Specifically, Evolent Health Inc (EVH), representing 0.01% of FHLC, has seen purchases from nine directors and officers, totaling approximately $1.34 million based on recent Form 4 filings, with CEO Seth Blackley purchasing the largest block of shares.

Analysis

The Fidelity MSCI Health Care Index ETF (FHLC) exhibits a notable pattern where 12.8% of its weighted underlying holdings have experienced insider buying over the past six months, suggesting potential undervaluation or positive forward-looking sentiment within certain segments of the healthcare sector. Evolent Health Inc (EVH), although a minor 0.01% constituent of FHLC with a total ETF holding valued at $371,043, serves as a prominent example of this trend. Recent Form 4 filings detail that nine EVH directors and officers, including CEO Seth Blackley (55,225 shares at $9.01 for $497,577) and Director Richard M. Jelinek (30,000 shares at $9.12 for $273,750), collectively purchased approximately $1.346 million worth of EVH stock. These transactions, executed at prices ranging from $8.75 to $9.44 per share against a last trade price of $8.97 for EVH, represent a substantial vote of confidence from company leadership, with the total insider purchase value significantly exceeding FHLC's entire stake in the company.

Key Decisions for Investors

• Investors should closely examine Evolent Health (EVH) due to significant, broad-based insider purchases totaling approximately $1.346 million from nine key insiders, including the CEO, suggesting a strong internal belief in potential undervaluation or positive catalysts.
• Consider this pattern of insider buying as a strong positive signal for EVH, especially as share purchases occurred at various price points between $8.75 and $9.44, reinforcing conviction around the recent trade price of $8.97.
• While EVH's direct impact on FHLC is minimal due to its 0.01% weighting, the notable 12.8% of FHLC's broader holdings experiencing insider buying warrants deeper investigation into other specific healthcare companies within the ETF that demonstrate similar strong insider conviction.